# Resilient Biotics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/resilient-biotics

- Industry: Biotechnology
- Headquarters: Durham, US
- Website: www.resilientbiotics.com
- Total disclosed funding: $7.2M
- Latest round: Series A (Dec 2, 2020)
- Investors on record: 5

## About

Based in North Carolina, US, and founded in 2016, Resilient Biotics Inc. develops microbiome-based live biotherapeutics that decreases or replaces antibiotics in the animal health industry. The company was co-founded by Christopher Belnap, currently its CEO, and Greg Werner.

The company's process combines bioinformatics and machine learning tools in identifying new microbial strains and parsing complex microbiome datasets. Resilient Biotics flagship product, RBX001, an intranasal and non-antibiotic treatment that prevent bovine respiratory disease (BRD).

The company plans to expand product development around similar non-antibiotic microbiome-derived products for other animals. Resilient Biotics also exploring potential therapeutics for swine and poultry.

## Funding rounds

- Series A, Dec 2, 2020, $7.2M — Viking Global Investors, Elanco Animal Health, Inc., Berkeley Catalyst Fund, Fulcrum Global Capital, Innovation in Motion

## Investors

- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series A
- Elanco Animal Health, Inc. — Series A
- Berkeley Catalyst Fund (https://capitalatlas.ai/funds/berkeley-catalyst-fund) — Series A
- Fulcrum Global Capital (https://capitalatlas.ai/funds/fulcrum-global-capital) — Series A
- Innovation in Motion (https://capitalatlas.ai/funds/innovation-in-motion) — Series A